Role of FDG-PET/CT in evaluating surgical outcomes of operable breast cancer - Usefulness for malignant grade of triple-negative breast cancer

Breast

Volumn 22, Issue 5, 2013, Pages 958-963

  Ohara, Masahiro ^a   Shigematsu, Hideo ^a   Tsutani, Yasuhiro ^a   Emi, Akiko ^a   Masumoto, Norio ^a   Ozaki, Shinji ^a   Kadoya, Takayuki ^a   Okada, Morihito ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

Author keywords

Breast cancer; PET CT; Prognosis; SUVmax; Triple negative breast cancer

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUORODEOXYGLUCOSE; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL EVALUATION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DISEASE FREE SURVIVAL; HUMAN; LYMPH NODE METASTASIS; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PET SCANNER; PREDICTION; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RECURRENCE RISK; TRIPLE NEGATIVE BREAST CANCER; TUMOR INVASION; TUMOR VOLUME;

AREA UNDER THE CURVE; AUC; BREAST CANCER; COMPUTED TOMOGRAPHY; CT; DFS; DISEASE-FREE SURVIVAL; ER; ESTROGEN RECEPTOR; FDG-PET; HER2; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR TYPE 2; IDC; INVASIVE DUCTAL CARCINOMA; MAXIMUM STANDARDIZED UPTAKE VALUE; PET/CT; PGR; PROGESTERONE RECEPTOR; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; ROC; SUV(MAX); TRIPLE-NEGATIVE BREAST CANCER; [18F]-FLUORO-2-DEOXYGLUCOSE-POSITRON EMISSION TOMOGRAPHY;

ADULT; AGED; AGED, 80 AND OVER; AREA UNDER CURVE; CARCINOMA, DUCTAL, BREAST; DISEASE-FREE SURVIVAL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MIDDLE AGED; MULTIMODAL IMAGING; NEOPLASM GRADING; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; ROC CURVE; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84884168587     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2013.05.003     Document Type: Article

References (35)

1. Vansteenkiste J.F., Stroobants S.G., Dupont P.J., De Leyn P.R., Verbeken E.K., Deneffe G.J., et al. Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: an analysis of 125 cases. JClin Oncol 1999, 17:3201-3206. Leuven Lung Cancer Group.
2. Santiago J.F., Gonen M., Yeung H., Macapinlac H., Larson S. Aretrospective analysis of the impact of 18F-FDG PET scans on clinical management of 133 breast cancer patients. QJ Nucl Med Mol Imaging 2006, 50:61-67.
3. Port E.R., Yeung H., Gonen M., Liberman L., Caravelli J., Borgen P., et al. 18F-2-fluoro-2-deoxy-D-glucose positron emission tomography scanning affects surgical management in selected patients with high-risk, operable breast carcinoma. Ann Surg Oncol 2006, 13:677-684.
4. Okada J., Yoshikawa K., Itami M., Imaseki K., Uno K., Itami J., et al. Positron emission tomography using fluorine-18-fluorodeoxyglucose in malignant lymphoma: a comparison with proliferative activity. JNucl Med 1992, 33:325-329.
5. Kubota K., Matsuzawa T., Fujiwara T., Ito M., Hatazawa J., Ishiwata K., et al. Differential diagnosis of lung tumor with positron emission tomography: a prospective study. JNucl Med 1990, 31:1927-1932.
6. Okazumi S., Isono K., Enomoto K., Kikuchi T., Ozaki M., Yamamoto H., et al. Evaluation of liver tumors using fluorine-18-fluoro-2-deoxy-D-glucose PET. JNucl Med 1992, 33:339-344.
7. Groheux D., Giacchetti S., Rubello D., Al-Nahhas A., Moretti J.L., Espié M., et al. The evolving role of PET/CT in breast cancer. Nucl Med Commun 2010, 31:271-273.
8. Berriolo-Riedinger A., Touzery C., Riedinger J.M., Toubeau M., Coudert B., Arnould L., et al. [18F]FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging 2007, 34:1915-1924.
9. Schirrmeister H., Kuhn T., Guhlmann A., Santjohanser C., Hörster T., Nüssle K., et al. Fluorine-18 2-deoxy-2-fluoro-Dglucose PET in the preoperative staging of breast cancer: comparison with the standard staging procedures. Eur J Nucl Med 2001, 28:351-358.
10. Fuster D., Duch J., Paredes P., Velasco M., Muñoz M., Santamaría G., et al. Preoperative staging of large primary breast cancer with [18F] fluorodeoxyglucose positron emission tomography/computed tomography compared with conventional imaging procedures. JClin Oncol 2008, 26:4746-4751.
11. Dose J., Bleckmann C., Bachmann S., Bohuslavizki K.H., Berger J., Jenicke L., et al. Comparison of fluorodeoxyglucose positron emission tomography and "conventional diagnostic procedures" for the detection of distant metastases in breast cancer patients. Nucl Med Commun 2002, 23:857-864.
12. Klaeser B., Wiederkehr O., Koeberle D., Mueller A., Bubeck B., Thuerlimann B. Therapeutic impact of 2-[fluorine-18] fluoro-2-deoxy-D-glucose positron emission tomography in the pre- and postoperative staging of patients with clinically intermediate or high-risk breast cancer. Ann Oncol 2007, 18:1329-1334.
13. Landheer M.L., Steffens M.G., Klinkenbijl J.H., Westenberg A.H., Oyen W.J. Value of fluorodeoxyglucose positron emission tomography in women with breast cancer. Br J Surg 2005, 92:1363-1367.
14. Dirisamer A., Halpern B.S., Flory D., Wolf F., Beheshti M., Mayerhoefer M.E., et al. Integrated contrast-enhanced diagnostic whole-body PET/CT as a first-line restaging modality in patients with suspected metastatic recurrence of breast cancer. Eur J Radiol 2010, 73:294-299.
15. Okada M., Nakayama H., Okumura S., Daisaki H., Adachi S., Yoshimura M., et al. Multicenter analysis of high-resolution computed tomography and positron emission tomography/computed tomography findings to choose therapeutic strategies for clinical stage IA lung adenocarcinoma. JThorac Cardiovasc Surg 2011, 131:1384-1391.
16. Tsutani Y., Miyata Y., Misumi K., Ikeda T., Mimura T., Hihara J., et al. Difference in prognostic significance of maximum standardized uptake value on [18F]-fluoro-2-deoxyglucose positron emission tomography between adenocarcinoma and squamous cell carcinoma of the lung. Jpn J Clin Oncol 2011, 41:890-896.
17. Buck A., Schirrmeister H., Kuhn T., Shen C., Kalker T., Kotzerke J., et al. FDG uptake in breast cancer: correlation with biological and clinical prognostic parameters. Eur J Nucl Med Mol Imaging 2002, 29:1317-1323.
18. Smith T.A., Sharma R.I., Thompson A.M., Paulin F.E. Tumor 18F-FDG incorporation is enhanced by attenuation of P53 function in breast cancer cells invitro. JNucl Med 2006, 47:1525-1530.
19. Dehdashti F., Mortimer J.E., Siegel B.A., Griffeth L.K., Bonasera T.J., Fusselman M.J., et al. Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and invitro receptor assays. JNucl Med 1995, 36:1766-1774.
20. Crippa F., Seregni E., Agresti R., Chiesa C., Pascali C., Bogni A., et al. Association between [18F]fluorodeoxyglucose uptake and postoperative histopathology, hormone receptor status, thymidine labelling index and p53 in primary breast cancer: a preliminary observation. Eur J Nucl Med 1998, 25:1429-1434.
21. Avril N., Menzel M., Dose J., Schelling M., Weber W., Jänicke F., et al. Glucose metabolism of breast cancer assessed by 18F-FDG PET: histologic and immunohistochemical tissue analysis. JNucl Med 2001, 42:9-16.
22. Bos R., van Der Hoeven J.J., van Der Wall E., van Der Groep P., van Diest P.J., Comans E.F., et al. Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. JClin Oncol 2002, 20:379-387.
23. Kumar R., Chauhan A., Zhuang H., Chandra P., Schnall M., Alavi A. Clinicopathologic factors associated with false negative FDG-PET in primary breast cancer. Breast Cancer Res Treat 2006, 98:267-274.
24. Groheux D., Giacchetti S., Moretti J.L., Porcher R., Espié M., Lehmann-Che J., et al. Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer. Eur J Nucl Med Mol Imaging 2011, 38:426-435.
25. Lee J.R., Madsen M.T., Bushnel D., Menda Y. Athreshold method to improve standardized uptake value reproducibility. Nucl Med Commun 2000, 21:685-690.
26. The Japanese Breast Cancer Society General rules for clinical and pathological recording of breast cancer 2008, Kanehara, Tokyo. 16th ed.
27. Oshida M., Uno K., Suzuki M., Nagashima T., Hashimoto H., Yagata H., et al. Predicting the prognoses of breast carcinoma patients with positron emission tomography using 2-deoxy-2-fluoro[18F]-D-glucose. Cancer 1998, 82:2227-2234.
28. Foulkes W.D., Stefansson I.M., Chappuis P.O., Bégin L.R., Goffin J.R., Wong N., et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. JNatl Cancer Inst 2003, 1482-1485.
29. O'Shaughnessy J., Osborne C., Pippen J.E., Yoffe M., Patt D., Rocha C., et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. NEngl J Med 2011, 364:205-214.
30. Silver D.P., Richardson A.L., Eklund A.C., Wang Z.C., Szallasi Z., Li Q., et al. Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. JClin Oncol 2010, 28:1145-1153.
31. Tchou J., Sonnad S.S., Bergey M.R., Basu S., Tomaszewski J., Alavi A., et al. Degree of tumor FDG uptake correlates with proliferation index in triple-negative breast cancer. Mol Imaging Biol 2010, 12:657-662.
32. Goldhirsch A., Ingle J.N., Gelber R.D., Coates A.S., Thürlimann B., Senn H.J., et al. Thresholds for therapies: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer. Ann Oncol 2009, 20:1319-1329.
33. Offersen B.V., Sorensen F.B., Knoop A., Overgaard J., et al. The prognostic relevance of estimates of proliferative activity in early breast cancer. Histopathology 2003, 43:573-582. Danish Breast Cancer Cooperative Tumour Biology Committee.
34. Fasanella S., Leonardi E., Cantaloni C., Eccher C., Bazzanella I., Aldovini D., et al. Proliferative activity in human breast cancer:Ki-67 automated evaluation and the influence of different Ki-67 equivalent antibodies. Diagn Pathol 2011, 6:S7.
35. Nakayama H., Okumura S., Daisaki H., Kato Y., Uehara H., Adachi S., et al. Value of integrated positron emission tomography revised using a phantom study to evaluate malignancy grade of lung adenocarcinoma: a multicenter study. Cancer 2010, 116:3170-3177.